Payment overview · 2025
General Payments
$93.45
4 reported records · 3 companies
Healthcare provider profile · identity verified
Pablo Sobero, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORENO VALLEY, CA · NPI 1659314318
Verified facts
What the public records show
CMS Open Payments records show Pablo Sobero, M.D. received $93.45 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 52.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.29 | 52.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.68 | 27.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.48 | 19.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $93.45 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 856 | 293 |
| Lisinopril | Lisinopril | 538 | 171 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 516 | 157 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 452 | 113 |
| Metformin Hcl | Metformin Hcl | 444 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 108 |
| Furosemide | Furosemide | 354 | 105 |
| Valsartan | Valsartan | 353 | 104 |
| Gabapentin | Gabapentin | 348 | 120 |
| Ibuprofen | Ibuprofen | 343 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 98 |
| Omeprazole | Omeprazole | 303 | 99 |
| Potassium Chloride | Potassium Chloride | 268 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 90 |
| Losartan Potassium | Losartan Potassium | 244 | 81 |
| Trazodone Hcl | Trazodone Hcl | 233 | 72 |
| Simvastatin | Simvastatin | 212 | 68 |
| Alendronate Sodium | Alendronate Sodium | 195 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 191 | 61 |
| Benazepril Hcl | Benazepril Hcl | 179 | 53 |
| Glimepiride | Glimepiride | 174 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 173 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 59 |
| Famotidine | Famotidine | 138 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 54 |
| Pregabalin | Pregabalin | 128 | 38 |
| Meloxicam | Meloxicam | 120 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 40 |
| Montelukast Sodium | Montelukast Sodium | 102 | 36 |
| Lorazepam | Lorazepam | 99 | 26 |
| Carvedilol | Carvedilol | 98 | 34 |
| Alprazolam | Alprazolam | 87 | 16 |
| Azithromycin | Azithromycin | 86 | 71 |
| Tramadol Hcl | Tramadol Hcl | 86 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 25 |
| Atenolol | Atenolol | 82 | 25 |
| Baclofen | Baclofen | 82 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 25 |
| Eliquis | Apixaban | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 22 |
| Nitroglycerin | Nitroglycerin | 69 | 42 |
| Telmisartan | Telmisartan | 69 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 36 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 23 |
| Ozempic | Semaglutide | 60 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 11 |
| Finasteride | Finasteride | 58 | 21 |
| Linzess | Linaclotide | 58 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 19 |
| Sertraline Hcl | Sertraline Hcl | 53 | 22 |
| Spiriva Handihaler | Tiotropium Bromide | 49 | 14 |
| Latanoprost | Latanoprost | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 17 |
| Ketoconazole | Ketoconazole | 46 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Allopurinol | Allopurinol | 45 | 16 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 43 | 15 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | 16 |
| Nifedipine Er | Nifedipine | 34 | 11 |
| Cephalexin | Cephalexin | 33 | 30 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Folic Acid | Folic Acid | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 30 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Prednisone | Prednisone | 30 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | 11 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 13 |
| Levofloxacin | Levofloxacin | 27 | 24 |
| Risperidone | Risperidone | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | 12 |
| Nystatin | Nystatin | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Klor-Con 8 | Potassium Chloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93.45 · 4 records | Lilly USA, LLC | Dexcom G6 Transmitter, GVOKE HYPOPEN, MOUNJARO, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error